The study, development and clinical studies we perform at Argutari Pharma are assisting doctors, physicians as well as their global patients, more effectively cope with a number of medical conditions along with associated suffering.
Regardless of our achievements with this, we continue to focus our development and research relating to additional disease areas that presently have substantial unmet requirements, and invariably with a superior quality of life for patients as the primary goal. We'll always look for remedies for a variety of conditions that presently have little or no remedies, some examples below:
Endometriosis is an agonizing condition associated with the uterus that is affecting around 175 million pre-menopausal women globally. We're seeking to aid patients to medically control endometriosis and its typically incapacitating pain. As of March 2018, we have carried out one of the biggest studies in North America thus far, and proceed to focus on a fresh therapy for the disease’s most typical symptoms.
Uterine fibroids are noncancerous tumors found in uterus muscle tissue. Fibroids tend to be most widespread in women between 30-40 years of age and is related to a variety of debilitating symptoms. For women experiencing substantial menstrual bleeding related to uterine fibroids, there's minimal non-surgical treatments. We currently have a number of ongoing clinical tests assessing the effectiveness of a brand new treatment which can help control the conditions of uterine fibroids.
Cystic Fibrosis is a rare life-threatening hereditary disease that affects between 75,000 and 110,000 patients worldwide, it affects the lungs and digestive system. In the US and UK, the average life expectancy is 35 to 40 years. In underdeveloped, poorer countries, life expectancy is under 15. At present there is no cure for Cystic Fibrosis. We are actively assessing investigational compounds and are at the beginning of clinical stages of a multi blend therapy.
Diabetic nephropathy, also known as diabetic kidney disease, is a typical consequence associated with diabetes and the major reason behind chronic kidney disease throughout the world. We are currently performing a clinical analysis to evaluate the impact of an investigational medicine on advancement of kidney disease in patients with stage 2 to 4 CKD along with type-2 diabetes.